oru.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
The national incidence of PML in Sweden, 1988-2013
Department of Clinical Neuroscience, Division of Neurology, Karolinska Institutet, Stockholm, Sweden.
Center for Pharmacoepidemiolog, Karolinska Institutet, Stockholm, Sweden.
Center for Pharmacoepidemiolog, Karolinska Institutet, Stockholm, Sweden.
Department of Clinical Neuroscience, Division of Neurology, Karolinska Institutet, Stockholm, Sweden.
Visa övriga samt affilieringar
2018 (Engelska)Ingår i: Neurology, ISSN 0028-3878, E-ISSN 1526-632X, Vol. 90, nr 6, s. E498-E506Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Objective: To investigate the incidence of progressive multifocal leukoencephalopathy (PML) and patient characteristics in Sweden between 1988 and 2013.

Methods: All PML diagnoses in Sweden between 1988 and 2013 were identified in the National Patient Register. Information to validate the diagnosis and patient characteristics was obtained from medical records.

Results: Medical record review classified 108 out of 250 patients (43%) as definite (n = 84), probable (n = 4), or possible (n = 20) PML according to diagnostic criteria. Accurate diagnoses were more common in records obtained from neurology departments (82% of patients seen in neurology departments) compared with other departments (31%) (p < 0.001). The incidence of PML increased from a largely stable level at 0.026 (95% confidence interval [CI] 0.021-0.031) per 100,000 individuals per year during 1988-2010 to 0.11 (95% CI 083-0.137) during 2011-2013, during which time there was a notable increase (p < 0.001). Hematologic malignancies (n = 34), HIV/AIDS (n = 33), and autoimmune disease (n = 23) were the most common underlying diseases. Treatment with a monoclonal antibody prior to PML diagnosis was identified in 26 patients.

Conclusion: An increased incidence of PML in Sweden was observed and coincided with the prior use of monoclonal antibody treatment. The high level of misdiagnosis emphasizes the importance of immediate contact with a neurology center upon suspicion of PML.

Ort, förlag, år, upplaga, sidor
Lippincott Williams & Wilkins, 2018. Vol. 90, nr 6, s. E498-E506
Nationell ämneskategori
Neurologi
Identifikatorer
URN: urn:nbn:se:oru:diva-66935DOI: 10.1212/WNL.0000000000004926ISI: 000427800200007PubMedID: 29321229OAI: oai:DiVA.org:oru-66935DiVA, id: diva2:1205489
Forskningsfinansiär
Hjärnfonden
Anmärkning

Funding Agencies:

F. Hoffmann-La Roche Ltd.  

Stockholm County Council  

Swedish Medical Research Council  

Karolinska Institutet 

Tillgänglig från: 2018-05-14 Skapad: 2018-05-14 Senast uppdaterad: 2018-09-04Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextPubMed

Personposter BETA

Montgomery, Scott

Sök vidare i DiVA

Av författaren/redaktören
Montgomery, Scott
Av organisationen
Institutionen för medicinska vetenskaper
I samma tidskrift
Neurology
Neurologi

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 114 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf